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The baculovirus expression vector system (BEVS) is a widely used platform for the production of recombinant eukaryotic proteins. However, the BEVS has limitations in comparison to other higher eukaryotic expression systems. First, the insect cell lines used in the
BEVS cannot produce glycoproteins with complex-type N-glycosylation patterns. Second,
protein production is limited as cells die and lyse in response to baculovirus infection. To
delay cell death and lysis, we transformed several insect cell lines with an expression plasmid harboring a vankyrin gene (P-vank-1), which encodes an anti-apoptotic protein. Specifically, we transformed Sf9 cells, Trichoplusia ni High FiveTM cells, and SfSWT-4 cells, which
can produce glycoproteins with complex-type N-glycosylation patterns. The latter was
included with the aim to increase production of glycoproteins with complex N-glycans,
thereby overcoming the two aforementioned limitations of the BEVS. To further increase
vankyrin expression levels and further delay cell death, we also modified baculovirus vectors
with the P-vank-1 gene. We found that cell lysis was delayed and recombinant glycoprotein
yield increased when SfSWT-4 cells were infected with a vankyrin-encoding baculovirus. A
synergistic effect in elevated levels of recombinant protein production was observed when
vankyrin-expressing cells were combined with a vankyrin-encoding baculovirus. These effects
were observed with various model proteins including medically relevant therapeutic proteins.
In summary, we found that cell lysis could be delayed and recombinant protein yields could
be increased by using cell lines constitutively expressing vankyrin or vankyrin-encoding
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Introduction
The baculovirus expression vector system (BEVS, aka
Baculovirus insect cell system, BICS) is a recombinant protein production platform that combines insect cells with
recombinant baculovirus vectors1,2 and was recently
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reviewed by Refs. 3 and 4. In comparison to other higher
eukaryotic recombinant protein production platforms, the
BEVS quickly produces large amounts of properly folded
proteins. Additional advantages of the BEVS include the
ability to add eukaryotic post-translational modifications,
including O- and N-linked glycosylation, at the correct sites.
Moreover, multiple genes of interest can be encoded by the
same recombinant baculovirus,5–7 and large DNA fragments
can be cloned into the baculoviral vectors.3,8 These advantages have led to widespread use of the BEVS for various
applications, including the production of recombinant proteins for both basic and applied research, as well as the production of recombinant proteins for immunotherapy
treatment (e.g., ProvengeTM), prescription medicine, and vaccine applications3,4 such as the FDA-licensed products CervarixTM and FluBlokTM.9–11
One major limitation of the BEVS is that baculovirus
infection results in cell death and lysis, which limits baculoviral protein expression to the window of time between the
onset of late viral gene expression and the time of cell
death.12 Thus, protein expression is typically restricted to 3
days following infection. Furthermore, the insect cell secretory pathway is compromised during the later stages of baculovirus infection, limiting the extent to which secreted
recombinant proteins can be folded and secreted into the
extracellular medium. Secretory pathway impairment is
caused, at least to some extent, by the accumulation of large
amounts of virally encoded chitinase and cathepsin (a protease) in the secretory pathway.13,14 Following lysis, viral
cathepsin is released into the culture supernatant, and can
degrade recombinant proteins after being activated by treatment with chaotropic reagents such as SDS or low pH. To
address the negative impact of baculovirus chitinase and
cathepsin on secretory pathway protein yield and integrity,
baculovirus vectors lacking chitinase and cathepsin were
developed.15,16
Non-lytic or delayed lytic baculovirus vectors have been
used to delay cell death and lysis and improve production
levels and integrity of recombinant proteins.17,18 GomezSebastian et al. engineered a novel expression cassette containing various baculovirus genomic elements such as transactivators IE1 and IE0 and enhancer sequences.18 Insect
cells infected with those viruses showed increased cell viability and integrity after infection, and an increase in recombinant protein yields. A similar effect was achieved when
the baculovirus apoptotic inhibitor P35 was constitutively
expressed from the insect cells.19 However, the overexpression of IAP-1 and IAP-2 did not consistently inhibit apoptosis in AcMNPV.20,21
An alternative approach to delay lysis of baculovirusinfected cells is the expression of viral ankyrins (vankyrins)
derived from an insect polydnavirus, Campoletis sonorensis
ichnovirus (CsIV).22 Baculovirus-infected Sf9 cells constitutively expressing one of two vankyrin proteins (P-vank-1 or
I2-vank-3) exhibit a delay in cell lysis due to inhibition of
apoptosis, with some cells surviving several days longer than
normal.22 The nature of the vankyrin proteins and studies of
their activity suggest the antiapoptotic actions result from
modulation of host cellular immune responses to virus infection.22-24 Specifically, experimental evidence suggests vankyrin proteins are functional I-jB homologs that act on the
NF-jB signaling pathway to alter cellular immunity at the
transcriptional level to block apoptosis.25,26
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A second major limitation of the BEVS is the inability to
produce N-glycoproteins with human-type N-glycan structures. This is an important limitation, as glycosylation can
affect protein half-life, stability, function, structure, and/or
immunogenicity,27,28 and over 50% of human proteins are
glycosylated.29 Because glycoproteins are involved in important physiological processes such as cell proliferation and
differentiation, blood clotting and immunity, many glycoproteins are pharmaceutically relevant and used as therapeutics
or in vaccines.8,27,30 Unfortunately, a large majority of glycoprotein therapeutics cannot be produced using conventional BEVS, because the N-linked glycans on glycoproteins
produced in the BEVS are different from those produced in
mammalian cells, and do not provide efficient therapeutic
effects. Specifically, the insect cell lines used in the BEVS
do not produce activated sialic acid and do not express sufficient levels of several glycosyltransferases to produce complex, terminally sialylated glycoproteins. Instead, insect cells
produce N-glycoproteins with paucimannose glycans, where
mammalian cells produce complex sugar groups with terminal sialic acids.31–33 Because the majority of medically relevant proteins are glycoproteins, this is an important
limitation of the BEVS. Consequently, recombinant glycoprotein biologicals that require human-type glycans for clinical efficacy have to be produced in mammalian expression
platforms, although the BEVS is superior in many
aspects.34–36
To address this limitation, both baculovirus vectors and
insect cells have been engineered with the enzymes required
to produce N-glycoproteins with human-type complex, terminally sialylated glycans.31–33,37,38 One such engineered cell
line is SfSWT-4, which is a Spodoptera frugiperda Sf9 cell
line derivative that has been engineered to stably express
glycosyltransferases necessary for N-glycan elongation, as
well as several enzymes required to produce and activate
sialic acid.39
The present study was designed to expand the utility of
the vankyrin technology and to address both of these major
limitations of the BEVS. Our goal was to increase recombinant glycoprotein productivity and humanize N-glycosylation
in the BEVS by expressing vankyrin in glyco-engineered
insect cells. To achieve this goal, we stably transformed
SfSWT-4 cells with the P-vank-1 gene and demonstrated
increased yields of secreted glycoproteins.
Furthermore, we demonstrated vankyrin expression
improves protein yields in cell lines other than S. frugiperda
cell lines. Several reports indicate Trichoplusia ni cells can
produce significantly higher levels of secreted proteins than
S. frugiperda cells.40–42 Here, we stably transformed High
FiveTM insect cells, which are a T. ni cell line, to express Pvank-1. We found the resulting VE-High Five cell line had
enhanced cell viability and recombinant protein production
as compared to the parental cell line.
Finally, we also describe new vankyrin-enhanced (VE)
baculovirus vectors. VE-baculoviruses prolonged survival of
infected insect cells compared to conventional baculoviruses,
and accumulation of secreted proteins increased. In addition,
a synergistic effect was seen when a VE-baculovirus was
used to infect VE-insect cells.
In summary, we have addressed major limitations in the
BEVS by demonstrating that vankyrin enhancement can significantly improve cell viability in several types of
baculovirus-infected cells, including a glycosylating cell line.
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As a result, secretion of recombinant proteins produced in
the VE-BEVS is prolonged with less protein degradation and
thus, protein accumulation is considerably increased relative
to conventional BEVS. Consequently, VE-BEVS offer a
novel, significant, adaptable, and proven improvement to the
BEVS platform for various applications.

Materials and Methods
Cell lines and growth conditions
Spodoptera frugiperda Sf9 cells and Trichoplusia ni High
FiveTM cells were acquired from Thermo Fisher Scientific
(Waltham, MA, USA). SfSWT-4 cells39 were provided by Dr.
Donald Jarvis from the University of Wyoming (Laramie,
WY, USA) and VE-Sf9 cells, which are referred to as VECL02 cells,24 were developed at ParaTechs Corp. (Lexington,
KY). These cells are also known as SuperSf9-2 (Oxford
Expression Technologies, Oxford, UK). Insect cells were
maintained in suspension culture in 125 ml-Erlenmeyer flasks
at 278C with shaking at 130–150 rpm. For each passage, insect
cell cultures were diluted with insect cell culture medium to a
seeding density of 1 3 106 cells mL21 in a volume of 25–
50 mL when the cell density reached 5 3 106 cells mL21. Sf9
and VE-CL02 cells were grown in Sf-900TMII serum-free
medium (Sf-900TM II SFM; Thermo Fisher Scientific). High
FiveTM (Thermo Fisher Scientific) and VE-High Five cells
were grown in Express FiveV serum-free medium (Express
FiveV SFM; Thermo Fisher Scientific) supplemented with
18 mM L-glutamine (Thermo Fisher Scientific) and 10 U of
heparin per ml (Sigma–Aldrich, St. Louis, MO). SfSWT-4 and
VE-SfSWT-4 cells were routinely grown in TNM-FH (Gemini
Bio-Products, West Sacramento, CA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and 1% pluronic F68 (both Thermo Fisher Scientific).
VE-High Five and VE-SfSWT-4 (“VE-SWT”) cells were
obtained by transforming cells with a Junonia coenia densovirus transformation vector encoding P-vank-1 from the
Campolitis sonorensis ichnovirus (CsIV; accession no.
AAX56953.1) as described for VE-CL02 cells.24 The effect
of vankyrin expression from several different insect and viral
promoters on recombinant protein production were evaluated, and the VE-High Five and VE-SWT cell lines with Pvank-1 expression under the control of the constitutive CsIV
AHv0.8 promoter were chosen for further evaluation. Stably
transformed VE cells were selected with 400 mg mL21
Geneticin G418 Sulfate (Thermo Fisher Scientific). Populations of antibiotic-resistant cells were amplified to generate
stable polyclonal VE-High Five and VE-SWT cell lines. The
expression of P-vank-1 RNA in transformed cell lines was
confirmed by RT-PCR. Stable polyclonal cell lines were
evaluated for recombinant protein production and performance relative to unmodified insect cells.
For monoclonal selection of VE-High Five cells, limiting
dilutions were prepared from individual polyclonal cell lines
using 50% 48-h-conditioned Express FiveV medium containing 400 mg mL21 Geneticin G418 Sulfate. Each dilution
containing a single cell was added to 96-well flat bottom tissue culture plates. Plates were sealed and allowed to incubate at 278C for 4 weeks, replacing the media once, before
clonal populations of positive antibiotic-resistant cells
reached confluency and were reseeded into new wells in 96
well plates containing 200 mL of conditioned medium per
well, and incubated for 1 week. Cells were seeded into a 48R

R

R

well plate for scale-up and amplification, and grown to confluency in the presence of 400 mg mL21 Geneticin G418
Sulfate prior to seeding into 24-well, and finally six-well
plates. When cells in six-well plates reached confluency,
monoclonal cell lines were started in T25 flasks. RT-PCR
was performed to confirm expression of P-vank-1 in the
monoclonal cell lines. YFP expression levels were then
quantified in monoclonal isolates after infection with recombinant YFP-BEVS (see below; Figure 1).
Monoclonal isolates of VE-SWT cells were obtained as previously described39 by limiting dilution using conditioned
TNM-FH medium, yielding 34 monoclonal VE-SWT cell lines
stably expressing P-vank-1. Each monoclonal isolate was
screened for the production of terminally sialylated glycoconjugates by cell surface staining with Texas Red conjugated
Sambucus nigra agglutinin (SNA43). Cell surface fluorescence
could be observed on all 34 VE-SWT monoclonal isolates, as
well on SfSWT-4 positive control cells, whereas Sf9 control
cells did not fluoresce, indicating VE-SWT cells produced terminally sialylated glycoconjugates as expected. The 34 monoclonal isolates were further screened for growth characteristics
and enhanced glycoprotein production. A clone designated
VE-SWT33 was selected for further experiments because it
uniformly grew without clumping or floating in monolayer and
consistently produced high levels of two mammalian model
glycoproteins, erythropoietin (EPO) and secreted alkaline
phosphatase (SEAP), when infected with recombinant baculoviruses encoding these proteins.
Baculovirus transfer vectors
pAcVE.02 and pAcVE.03 transfer vectors (Figure 3) are
modified from pAcVE.01 (ParaTechs, Lexington, KY) with
the addition of the honeybee melittin (HBM) signal peptide
to increase protein secretion.44 pAcVE.01 was synthesized
by GenScript (Piscataway, NJ, USA) and encodes, an 861 bp
ampicillin resistance gene (derived from pUC57), a 131 bp
SV40 polyadenylation signal, and genomic DNA fragments
from AcMNPV (accession NC_001623) to target the polyhedrin locus for in vivo homologous recombination and that
correspond to the polyhedrin promoter (nt 4425-4521), the
p10 promoter (nt 118728-118839), ORF603 (nt 3759-4364)
and its promoter and ORF1629 (nt 5287-6918) and its transcription termination signal. Downstream of the polyhedrin
promoter is a 92 bp multiple cloning site (MCS) containing
AvrII, BglII, BstZ17I, EagI, NcoI, NheI, SacII, SbfI, and
XhoI restriction sites, followed by a 6x His-tag to facilitate
protein purification and a stop codon. On the complementary
strand, downstream of the p10 promoter is the CsIV P-vank1 gene flanked by AflII restriction sites. A 137 bp fragment
comprising a 69 bp region encoding HBM signal peptide, a
PmeI restriction site, an 8x His-tag, and a MCS containing
NotI, SbfI, and NheI restriction sites was synthesized by
GenScript and cloned into pUC57 (HBM-pUC57). This plasmid was digested with AvrII and NheI to excise the 137 bp
insert, which was then ligated into the AvrII and NheI sites
of pAcVE.01, thereby replacing its MCS with the 137 bp
fragment, and chemically transformed into DH5a cells
(Thermo Fisher Scientific). The resulting plasmid was designated as pAcVE.02 (Figure 3A). pAcVE.03 was constructed
by inserting the HBM signal sequence upstream of the MCS
of pAcVE.01 using Infusion cloning (Takara, Mountain
View, CA). The HBM was PCR amplified from plasmid
HBM-pUC57 with primer set 335/343 (Table 1); each primer
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Figure 1. Vankyrin-enhanced cells have increased YFP fluorescence and viability compared to their parental cell line.
Legend: (A) Fluorescent images (3200 magnifications), (B) measured YFP fluorescence, and (C) cell viability for VE-CL02 and its parental cell
line Sf9 (top panels; Sf-900TMII medium), VE-High Five and its parental cell line High-FiveTM (middle panels; Express FiveV SFM medium), and
VE-SWT and its parental cell line SfSWT4 (bottom panel; TNM-FH medium with FBS) infected with a baculovirus encoding YFP (YFP-AcMNPV)
at a multiplicity of infection (MOI) of 5 is shown for days 2–5 post-infection. All infections were in static cultures with a cell density of 5 3 105
cells at the time of infection. Total YFP fluorescence for each infection (B) was determined by flow cytometry using the Guava easyCyte Flow
Cytometer as described in the Materials and Methods section. Percent viability (C) was determined by trypan blue staining as described in the Materials and Methods section. In (B) and (C), parental cell lines are indicated by gray bars, and Vankyrin-enhanced (VE) cell lines are represented by
black bars. The increase in cell viability in virus-infected VE-CL02 cells (C, top panel) from day 3 to day 4 can be explained by the difference in
total cell number. The data presented are means and standard deviations for triplicate determinations for each cell line in a single experiment. The
data presented here are representatives of multiple experiments performed from which equivalent results were obtained. Statistical significance
(P  0.05) as determined by the Student two-tailed t test for comparison of baculovirus-infected parental cells vs. baculovirus-infected VE-cells is
represented by an asterisk (*).
R

Table 1. Oligonucleotide Primers Used for PCR in this Study
Designation
Footnote
335
343
351
352
357
358
359
360
363
364

*
*
†
†
‡
‡
‡
‡
§
§

0

550 50 50 50 50 50 50 50 50 -

Sequence

Type of PCR or Oligonucleotide
0

ATAAATATACCTAGGATGAAATTTCTAGTAAACGTTGCC-3
GGCCATGGACCTAGGCGGATCAGCATAGA-30
GTATACAAAGATCTCAAGTACCGCGGTCG-30
CGACCGCGGTACTTGAGATCTTTGTATAC-30
GCTGATCCGCCtgGTCCATGGCC-30
GGCCATGGacCAGGCGGATCAGC-30
CGCTCTATCTAGCtgCACATCACCATC-30
GATGGTGATGTGcaGCTAGATAGAGCG-30
CCATGGGCCCCCCCTAGATTAATT-30
CTCGAGCCGATCGCCTGTACGGCA-30

Infusion
Infusion
Site-directed
Site-directed
Site-directed
Site-directed
Site-directed
Site-directed
Amplifying
Amplifying

mutagenesis
mutagenesis
mutagenesis
mutagenesis
mutagenesis
mutagenesis

*Underlined nucleotides of infusion primers correspond to pAcVE.01 sequence; non-underlined nucleotides correspond to HBM or signal peptide
sequence.
†
Substituted nucleotides in the site-directed mutagenesis primers are in bold and italicized.
‡
Bases surrounding the deleted adenine are lowercase.
§
Primers used for routine PCR amplification of erythropoietin gene were synthesized with either a NcoI or XhoI restriction site (underlined) for ease
of cloning.
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Table 2. Bacterial Plasmids and Bacmids Used in this Study
Plasmid
R

pGEMV-T Easy
pUC57
pEYFP-C1
pFastbacTM Dual
pAcVE.01
pAcVE.02
pAcVE.03
pAc.01
pAc.02
pAc.03
epo-pUC57
pKH25
epo-pAc.03
epo-pAcVE.03
seap-pUC57
seap-pAc.02
seap-pAcVE.02
pVL-YFP

Description

ColE1-based cloning vector; 3,015 bp, Apr (Promega #A1360)
ColE1-based cloning vector; 2,710 bp, Apr (GenScript #SD1176)
pBR322 origin vector containing Aequorea victoria GFP; 4,731 bp, Knr (Clontech, discontinued)
pUC-based vector containing MCSs after the polH and p10 promoters; 5,238 bp, Apr Gnr
(Thermo Fisher Scientific #10712–024)
Derivative of pUC57; described in materials and methods section
Derivative of pAcVE.01; described in materials and methods and Figure 4
Derivative of pAcVE.01; described in materials and methods and Figure 4
Derivative of pAcVE.01 where the 516 bp P-vank-1 gene has been deleted
Derivative of pAcVE.02 where the 516 bp P-vank-1 gene has been deleted
Derivative of pAcVE.03 where the 516 bp P-vank-1 gene has been deleted
607 bp codon optimized epo gene from human cells cloned into EcoRI site of pUC57
510 bp NcoI/XhoI DNA from epo-pUC57 containing epo (PCR primers 363/364) cloned into pGEMV-T Easy
504 bp NcoI/XhoI fragment from pKH25 containing epo with no stop codon cloned into pAc.03
504 bp NcoI/XhoI fragment from pKH25 containing epo with no stop codon cloned into pAcVE.03
509 bp codon optimized seap gene from human cells cloned into EcoRI site of pUC57
Derivative of seap-pAcVE.02 where the 516 bp P-vank-1 gene has been deleted
1,504 bp NotI/SbfI from seap-pUC57 containing seap with stop codon cloned into pAcVE.02
BamHI/SmaI fragment from pEYFP-C1 containing yfp cloned into pVL1392
R

Abbreviations: (Apr) ampicillin resistance, (Knr) kanamycin resistance, (Gnr) gentamicin resistance, (polH) polyhedrin, (seap) secreted embryonic
alkaline phosphatase, (epo) erythropoietin.

was designed to overlap both pAcVE.01 and the HBM
sequences. The HBM PCR fragment was then ligated into
the AvrII site of pAcVE.01, and the reaction product was
chemically transformed into DH5a cells. Insertion of the
HBM must be in frame with the restriction enzymes in the
pAcVE.01 MCS and the C-terminal 6x His-tag, but insertion
of the signal peptide resulted in three stop codons in this
DNA region. The stop codons were removed using sitedirected mutagenesis (Agilent Technologies, Santa Clara, CA
USA) to mutate G2732C (primer set 351/352), followed by
deletions of A2684 (primer set 357/358) and A2768 (primer
set 359/360). The resulting plasmid was designated
pAcVE.03 (Figure 3A). To enable evaluation of the
vankyrin-harboring baculoviruses, control transfer vectors
that are the non-vankyrin encoding versions of pAcVE.02
and pAcVE.03 were constructed by deleting the P-vank-1
gene using the restriction enzyme AflII and were named
pAc.02 and pAc.03, respectively. The sequences of all constructs were confirmed by dideoxy sequencing.
Recombinant baculovirus generation
A baculovirus transfer vector (pVL-YFP) encoding YFP
was obtained by excising the YFP open reading frame from
pEYFP-C1 (Takara; discontinued) using BamHI and SmaI
and cloning the fragment into the corresponding sites in the
MCS downstream of the polyhedrin promoter of a pVL1392based transfer vector (ParaTechs, KY; in house vector).
Genes encoding mature human secreted alkaline phosphatase
(SEAP; accession no. NP_001623.3) and erythropoietin
(EPO; accession no. NP_000790.2) were codon optimized
using the OPTIMIZER program (http://genomes.urv.es/OPTIMIZER/) with the AcMNPV codon bias (http://www.kazusa.
or.jp/), synthesized, and cloned into pUC57-based vectors
(GenScript), designated SEAP-pUC57 and EPO-pUC57
(Table 2). Neither gene included a start codon and native
signal peptide, as these genes were designed to use the HBM
start codon and signal peptide in pAcVE.02 and pAcVE.03
vectors. Further details regarding the construction of SEAP
and EPO baculovirus transfer vectors are described in
Table 2.
Recombinant baculoviruses encoding YFP, SEAP, or EPO
were generated through homologous recombination by

transfecting Sf9 cells with the transfer vector and the flashBAC GOLD AcMNPV DNA backbone (which does not
encode chitinase and cathepsin) using the manufacturer’s
instructions (Oxford Expression Technologies). The recombinant virus was amplified once or twice in 50-mL Sf9 cultures; filter sterilized using a 0.22-mm syringe filter, and
titered using the plaque assay method.45
Virus infections
The 5 3 105 insect cells were seeded into 12-well tissue
culture plates in 1 mL of their corresponding growth
medium. Once cells achieved confluency, cells were either
left uninfected or infected with a specified multiplicity of
infection (MOI) of recombinant baculovirus. Infections were
incubated at 278C for up to 10 days. On each day, baculovirus infected cells were monitored for cytopathic effects
(nuclear and cellular hypertrophy, grainy appearance, and
lysis), photomicrographs were taken with a Zeiss AX10
inverted microscope (Carl Zeiss Microscopy, Thornwood,
NY) and acquired using an AxioCamMR3 digital camera
(Carl Zeiss Microscopy). Samples were collected as specified
for each experiment.
YFP quantification
Sf9, VE-CL02, High Five, VE-High Five, SfSWT-4, and
VE-SWT cells were infected with YFP-AcMNPV at an MOI
of 5 in triplicate. On days 2–5 post-infection, photomicrographs and YFP fluorescence (300 ms exposure time) for
each infection well were captured using a Zeiss AX10
inverted fluorescence microscope with a 203 objective and
the AxioVision Rel. 4.6 program (Carl Zeiss Microscopy).
After gently collecting the cells, viability was determined by
staining cells with trypan blue (Thermo Fisher Scientific)
and counting viable and non-viable cells using an improved
Neubauer hemocytometer under magnification of a Zeiss
AX10 inverted microscope (Carl Zeiss Microscopy). To
quantify YFP fluorescence, insect cells were first counted in
triplicate utilizing a GuavaV easyCyte HT Sampling Flow
Cytometer and the guava InCyte Assay software module
(EMD Millipore, Hayward, CA). YFP fluorescence was then
measured using a 405-nm laser at a green spectral imaging
R
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band (525/30 nm) of the GuavaV easyCyteTM HT Sampling
Flow Cytometer. The total fluorescence of each infection
was determined with the GuavaV InCyte Assay software
module.
R

R

Cell viability assay of vankyrin-enhanced baculovirus
infected cells
Sf9 and SfSWT-4 insect cells were grown in 125 mLErlenmeyer flasks at 106 cells mL21 in their respective
medium in a final volume of 25 mL (Sf9) or 40 mL
(SfSWT-4), followed by an overnight incubation at 278C at
150 rpm. Next, cell density and viability were determined
before infecting the cells with recombinant baculovirus at
their optimal MOI (MOI of 5 for Ac.02, Ac.03, AcVE.02,
and AcVE.03 baculoviruses and MOI of 1 for epo-Ac.03 and
epo-AcVE.03 baculoviruses). Cultures were then incubated
for another 10 days. On each day, 90 mL of culture from
each flask was removed in duplicate, and the number of viable cells was determined by trypan blue staining as described
above.
Western blotting analysis
To evaluate expression levels and processing of the five
LDLa repeats of Manduca sexta pro-hemolymph protease-14
(proHP14), 1.6 3 106 Sf9 or VE-CL02 cells mL21 were
seeded in duplicate six-well plates in 2 mL Sf-900TM II
medium, and infected with a baculovirus encoding the five
LDLa repeats of proHP14 at an MOI of 5. Cells were incubated at 278C, and cell-free medium samples were collected
after 3, 5, and 7 days for SDS-PAGE (12%) followed by
Western blot analysis using 1:1,000 primary diluted anti-His
monoclonal antibody (GenScript) and 1:1,000 diluted goat
anti-mouse IgG-AP conjugate as the secondary antibody
(Bio-Rad, Hercules, CA).
Erythropoietin (EPO; 34 kDa) protein levels were determined by Western blotting from the infected cultures used in
the cell viability assay described earlier. On days 2–10 postinfection, a small sample of each culture was collected, and
cells were removed by centrifugation at 900 g for 10 min at
48C. Supernatants were stored at 48C until all of the samples
were collected. To determine recombinant protein levels per
mL of culture, 5 mL of supernatant were used for SDSPAGE (10%) followed by Western blot analysis using a
1:3,000 dilution of mouse monoclonal anti-His IgG2 antibody (GE Healthcare, Wauwatosa, WI) and a 1:300 dilution
of anti-mouse IgG horseradish peroxidase secondary antibody (GE Healthcare). Membranes were exposed to CN/
DAB substrate (Thermo Fisher Scientific) for 6 min, followed by rinsing the membrane with water to stop exposure.
Membranes were scanned using a BioRad Universal Hood II
Gel Doc UV transilluminator.
SEAP enzymatic assay
SfSWT-4 and VE-SWT cells were infected at an MOI of
1 with either seap-Ac.02 or seap-AcVE.02 baculoviruses in
triplicate wells. On days 3–5 post-infection, supernatants
were collected, cells were removed by centrifugation (900 g,
10 min, 48C), and the SEAP-containing supernatant was
stored at 48C until all of the samples were collected. A previously described enzymatic assay was used to measure
SEAP protein activity.46,47 Triplicate samples were heated at
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658C for 5 min, then 1 mL of each sample was added to 200
mL SEAP buffer (1 M diethanolamine, 0.5 mM MgCl2,
10 mM homoarginine) in a 96-well microtiter plate. Samples
were incubated at 378C for 10 min, pNPP working buffer
[20 mL; 5 mg p-nitrophenyl phosphate (Sigma) in pNPP
stock buffer (1 M diethanolamine, 0.5 mM MgCl2, 3.1 mM
NaN3, pH 9.8)] was added to each well, and the microtiter
plate was incubated at RT for 5 min in the dark. SEAP enzymatic activity was read at an absorbance of 405 nm using
the Epoch BioTek microplate spectrophotometer (Fisher
Scientific).
Statistics
Data are reported as mean 6 standard deviations. Statistical significance (P  0.05) between treatments was determined by the Student two-tailed t test.

Results and Discussion
We previously reported that expression of the Campoletis
sonorensis ichnovirus (CsIV) vankyrin gene P-vank-1 in the
Sf9–derived VE-CL02 cell line inhibits apoptosis and prolongs cell survival after baculovirus infection, UV irradiation, or treatment with an apoptosis-inducing chemical.24 In
the present study, we tested the hypothesis that expressing
vankyrin increases heterologous protein yields following
baculovirus infection of vankyrin-expressing insect cell lines
(VE-insect cells), or through infection with a baculovirus
vector encoding vankyrin (VE-baculovirus), or both. We
tested the previously established monoclonal VE-CL02 cell
line,24 and also tested Trichoplusia ni High FiveTM cells stably transformed with P-vank-1 expression constructs, as
High FiveTM cells have been reported to provide higher
recombinant protein yields than S. frugiperda cells.40–42
Finally, we also tested SfSWT-4 cells stably transformed
with a P-vank-1 expression construct, as SfSWT-4 can produce recombinant proteins with human-type N-glycans.39
Thus, we aimed to increase yield of glycoproteins with
authentic human-type N-glycans by combining vankyrinexpression with humanized glycoprotein processing. Monoclonal vankyrin-expressing cell lines are designated as VECL02, VE-High Five and VE-SWT.
Different cell culture media were tested to establish optimal growth conditions for SfSWT-4 and VE-SWT cell. We
found that the highest cell density (6 3 106 cells mL21) can
be reached when the VE-SWT cells were subcultured in
Sf900III medium. However, due to a faster doubling time of
VE-SWT cells grown in TNM-FH with FBS (24 h) compared to cells grown in Sf900III medium (72 h) in the first 3
days of culturing, we decided to routinely use TNM-FH
medium with FBS. In contrary to Invitrogen’s Mimic cells,
which require FBS as a source of sialic acid, SfSWT-4 and
VE-SWT cell lines are able to produce terminally sialylated
proteins in the absence of FBS.39
To test if recombinant protein yields were increased in
these three vankyrin-enhanced cell lines compared to their
respective parental cell lines, we infected cells with a YFPencoding baculovirus, and analyzed YFP fluorescence and
cell viability (Figure 1). Fluorescence images show that YFP
expression is considerably higher in VE-CL02 and VE-High
Five cells for the duration of the experiment when compared
to Sf9 and High FiveTM cells, respectively (Figure 1A).
These results were confirmed when we quantified YFP
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Figure 2. Vankyrin-enhanced Sf9 cells, VE-CL02, enhance protein yields of the five LDLa domains form of M. sexta pro-hemolymph
protease-14.
Legend: Western blot analysis of cell free extracts determining protein levels of the five LDLa domain of M. sexta pro-hemolymph protease 14
(proHP14) full-length protein (5 LDLa; top band) and intracellularly processed protein (4 LDLa; bottom band). Sf9 or VE-CL02 (designated V02)
cells grown in static culture in Sf-900TMII medium with a seeding cell density of 1.6 3 106 cells mL21 were infected with a baculovirus encoding
the five LDLa domains in proHP14 at MOI 5. Samples were collected on days 3, 5, and 7 post-infection, and protein extract from the same number
of viable cells was analyzed. The experiment was carried out with duplicate samples.

fluorescence using flow cytometry (Figure 1B). YFP fluorescence in VE-CL02 cells increases threefold on 3 days postinfection (dpi) and YFP fluorescence in VE-High Five cells
increases fivefold on 2 dpi compared to their parental cell
lines. Interestingly, average YFP fluorescence is higher in
VE-High Five cells compared to VE-CL02 or VE-SWT cells
(Figure 1B), which was in line with earlier reports of higher
protein expression in T. ni cell lines as compared to S. frugiperda cell lines. A significant increase in YFP fluorescence
is also detected in VE-SWT cells at 4 and 5 dpi (Figure 1B),
which correlates with increased longevity (Figure 1C). VECL02 cell viability is significantly higher than Sf9 on days 3
and 4 dpi, whereas the viability of YFP baculovirus-infected
VE-High Five is significantly higher than High FiveTM on
earlier days post-infection (days 2 and 3; Figure 1C). Thus,
early inhibition of apoptosis by vankyrin appears to be more
important for improving protein yields than its effect on viability at later time points in VE-CL02 and VE-High FiveTM
cells. Our observation of increased cell viability in cells
expressing P-vank-1 as compared to their parental cell lines
correlate with increased protein production in these cells
(compare Figure 1B with 1C). Hence, our results indicate
that constitutive expression of P-vank-1 in stably transformed insect cell lines leads to enhanced protein yields
through an increase in cell viability following baculovirus
infection. This study is especially relevant when considering
the use of the BEVS for the production of recombinant proteins for use in vaccines,34,48 as well as for use in applied
and basic research.
Next, we investigated whether vankyrin expression can
enhance yields of intracellularly processed proteins. Manduca sexta pro-hemolymph protease 14 (proHP14) is an initiating protease found in the serine proteinase pathway that is
involved in insect innate immunity.49–51 ProHP14 encodes a
signal peptide, five LDLa repeats—the first one of which
tends to be lost during intracellular processing50,51—one
Sushi domain, and one Wonton domain followed by a serine
protease catalytic domain. We set out to compare expression
levels of the five LDL repeats (LDLa1–5) of M. sexta
proHP14 in Sf9 and VE-CL02 cell lines. Immunoblotting
showed that at 3, 5, and 7 dpi, VE-CL02 cells have higher
levels of the regulatory domain LDLa1–5 as compared to
Sf9 cells (Figure 2). Furthermore, a majority of the recombinant protein had a molecular mass of 34 kDa when
expressed from VE-CL02 cells, whereas the processed product, with most likely the first LDLa domain removed by a
Sf9 intracellular processing enzyme (e.g., furin, convertase),52 is detected at around 27 kDa when proHP14 is
expressed in Sf9 cells (Figure 2). Even after 7 days post-

infection, VE-CL02 cells contain mainly the full-length protein, whereas only very low levels of protein of either size
could be detected in Sf9 cells (Figure 2). Our observations
support the notion that proteins expressed in VE-Sf9 cells
undergo less proteolysis, and that the integrity of the secretory pathway in those cells is preserved for an extended
period of time after baculovirus infection.
Following baculovirus infection, host gene transcription is
largely shut down and replaced with viral gene expression.53–55 Thus, vankyrin protein levels could potentially be
increased further through the use of recombinant baculovirus
vectors encoding P-vank-1. To produce and test such vectors,
we first generated two new dual-expression transfer vectors,
pAcVE.02, and pAcVE.03 (Figure 3A). Each transfer vector
has the P-vank-1 gene under transcriptional control of the
late, very strong baculovirus p10 promoter.3,56 These vectors
also contain a multiple cloning site (MCS) downstream of
the late, very strong polyhedrin promoter in the opposite orientation for insertion of a gene of interest.3,56 Because the
placement of purification tags are dependent on the type and
function of the protein to be expressed, we designed
pAcVE.02, which has an N-terminal 83 His-tag upstream
and in frame with the MCS, and pAcVE.03, which has a Cterminal 63 His-tag in frame with the MCS. pAcVE.02 and
pAcVE.03 both encode the honey bee melittin signal peptide
(HBM) upstream of the MCS to enhance secretion.44,57,58
These vankyrin-encoding transfer vectors and their counterparts lacking the P-vank-1 gene (as negative controls)
were then used to generate recombinant baculoviruses. Each
baculovirus was used to infect Sf9 insect cells, and cell viability was determined up to 10 days post-infection. Cell viability is significantly increased in cells infected with the
vankyrin-encoding baculoviruses as early as day 2 postinfection, and at 3 dpi cell viability is more than twice as
high in cells infected with baculovirus harboring the vankyrin gene compared to cells infected with control viruses
lacking the vankyrin gene (Figure 3B). A considerable number of cells are still viable 6 days after infection with a
vankyrin-enhanced baculovirus. These results indicate that
the P-vank-1 gene also prolongs cell viability when
expressed from the baculovirus vector.
To determine if baculovirus-mediated vankyrin expression
could also result in increased recombinant proteins yields,
we inserted a gene encoding human erythropoietin (EPO)
into pAcVE.03. Recombinant EPO is a glycoprotein hormone used to treat anemia, and its therapeutic efficacy
requires human-type N-glycosylation.59–62 SfSWT-4 cells
were infected with either a recombinant vankyrin-enhanced
baculovirus encoding EPO (EPO-AcVE.03) or a recombinant
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Figure 3. Vankyrin-encoding baculoviruses increase insect cell viability compared to non-vankyrin baculoviruses.
Legend: (A) New vankyrin-encoding transfer vectors pAcVE.02 and pAcVE.03 are shown. Each vector contains an ampicillin resistance gene
(ampR), the p10 promoter upstream of the vankyrin gene, a sv40 polyadenylation signal (sv40 PA signal), multi-cloning site (MCS; pAcVE.02:
NotI, SbfI, NheI; pAcVE.03: NcoI, SbfI, XhoI, BstZ17I, BglII, SacII, EagI), honey bee melittin signal peptide (HBM signal), his-tag, and ORF1629
(including polyA signal) and ORF603 (including promoter)—the two open reading frames that flank the polyhedrin gene in the AcMNPV genome.
(B) Viability of SfSWT4 cells infected with baculoviruses generated from transfer vectors pAc.02 and pAc.03, or the vankyrin-encoding counterpart
pAcVE.02 and pAcVE.03. Suspension cultures grown in Sf-900TMII were infected on day 0 with a MOI 5 of each baculovirus. The cell densities of
each culture at the time of infections were 2 3 106 cells mL21. Cell viability was determined at the on-set of the experiment (0 dpi before viral
infections) and 1–10 days post-infection (dpi) by staining cells with trypan blue and counting living cells with the hemocytometer. The data presented are means and standard deviations for duplicate determinations for each infection in a single experiment. The data presented here are representative of multiple experiments performed from which equivalent results were obtained. Statistical significance (P  0.05) as determined by the
Student two-tailed t test for comparison of non-vankyrin baculovirus infections vs. vankyrin-encoding baculovirus infections using the same transfer
vector backbone is represented by an asterisk (*).

baculovirus encoding EPO, but not vankyrin (EPO-Ac.03).
SfSWT-4 cells remain viable until 8 dpi when infected with
EPO-AcVE.03, whereas cells infected with EPO-Ac.03 are
mostly nonviable by 5 dpi (Figure 4A). A concomitant
increase in EPO yields was observed by immunoblotting
(Figure 4B), indicating that baculovirus-mediated vankyrin

expression resulted in enhanced protein yields when the gene
of interest was encoded by the same baculovirus.
Then, we explored if the prolonged cell viability and
increased recombinant protein yields observed with baculovirus mediated-vankyrin expression could be synergistically
combined with cell lines engineered to stably express
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Figure 4. Enhanced mammalian glycoprotein yields when expressed from a vankyrin-enhanced baculovirus.
Legend: (A) Cell viability was determined from suspension cultures grown in TNM-FH medium with FBS of uninfected SfSWT4 cells, of SfSWT4
cells infected with a MOI 1 of the erythropoietin (epo) encoding baculovirus (epo-Ac.03) or of the vankyrin-enhanced epo-baculovirus (epoAcVE.03) 0–10 days post-infection (dpi). The cell densities of each culture at the time of infection (0 days) were  1 3 106 cells mL21. The data
presented here are representative of multiple (>3) experiments performed from which equivalent results were obtained. Statistical significance as
determined by the Student two-tailed t test for comparison of epo-Ac.03 infected SfSWT4 cells vs. epo-AcVE.03 infected SfSWT4 cells and is represented by either one asterisk (*; P  0.05) or two asterisks (**; P  0.01). (B) Western blot analysis determining protein levels of glycosylated erythropoietin (epo; 31 kDa compared to unglycosylated epo at 18.4 kDa69) in 5 lL culture supernatant for SfSWT4 cells infected with the epo-encoding
baculoviruse (epo-Ac.03) or vankyrin enhanced baculovirus encoding epo (epo-AcVE.03) at an MOI of 1. Samples were collected on days 2, 4, 6, 8,
and 10 post-infection.

vankyrin. Thus, we evaluated the production of secreted
alkaline phosphatase (SEAP) using a VE-baculovirus in
SfSWT-4 and VE-SWT cells. Clinical trials have shown
promise for the use of SEAP in the treatment of acute renal
failure, sepsis, and ulcerative colitis,63 and SEAP has been
shown to improve outcomes in patients undergoing cardiac
bypass surgery.64 Furthermore, SEAP can be accurately
quantified using an enzymatic assay.46,47
Higher alkaline phosphatase activity is detected in supernatants of infected VE-SWT cells compared to those of
SfSWT-4 cells, irrespective of the type of baculovirus used
(Figure 5). These observations further support the hypothesis
that constitutive vankyrin expression increases recombinant
protein yields. This result is consistent with results obtained
by Lin et al. where Sf9 cells constitutively expressing
AcMNPV P35 were infected with a recombinant SEAP
baculovirus, and significantly higher protein levels were
detected in that cell line compared to the parental cell line.19
Higher alkaline phosphatase activity is also observed when
either SfSWT-4 or VE-SWT cells were infected with a
vankyrin-enhanced baculovirus encoding SEAP (SEAPAcVE.02) as compared to infection with a baculovirus
encoding SEAP but not vankyrin (SEAP-Ac.02; Figure 5).
Similar data is seen when comparing SEAP-AcVE.03 to
SEAP-Ac.03 virus infections (data not shown).
The highest levels of alkaline phosphatase activity are
detected when vankyrin-enhanced insect cells (VE-SWT) are
infected with a vankyrin-enhanced baculovirus encoding
SEAP (SEAP-AcVE.02). At 5 dpi, we observed a fivefold

increase in SEAP activity in the VE-SWT cells infected with
SEAP-AcVE.02 compared to SfSWT-4 cells infected with
SEAP-Ac.02, a combination lacking any vankyrin expression. Taken together, these results suggest that the positive
effects observed with cell-mediated and baculovirusmediated vankyrin expression can be synergistically combined. Possibly, this combination provides vankyrin proteins
early in infection from host cell expression, and during the
late phase of infection from strong viral promoters, while
vankyrin expression from stably integrated gene declines.65
In contrary to conventional BEVS where poor protein
expression is often caused by loss of integrity of the secretory pathway during the late stages of baculovirus infection,66 we have previously shown that the secretory pathway
is still functional in a vankyrin-enhanced Sf9 cell line after
infection with a baculovirus expressing a secreted protein.67
Here we report that the accumulation of two mammalian
glycoproteins (Figures 4 and 5) in the medium continue to
increase when expressed from a vankyrin-enhanced baculovirus whereas protein accumulation ceased (Figure 5) or
declined (Figure 4) over time when cells were infected with
conventional baculovirus. Taken together, these results support the hypothesis that due to its anti-apoptotic function,
vankyrin has a positive effect on the integrity of the secretory pathway.
Several recombinant vaccines are produced in the
BEVS,47 but this platform is not used to produce glycoprotein therapeutics, as most of these require complex, humantype glycosylation patterns, which the insect cell lines used
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Figure 5. Synergistic effect on protein yield using a vankyrin-encoding baculovirus to infect vankyrinenhanced insect cells.
Legend: Relative activity of secreted embryonic alkaline phosphatase (SEAP), measured at an absorbance of 405 nm, for uninfected SfSWT4 and
VE-SWT cells (solid light colored bars), SfSWT4 (dark striped bar) and VE-SWT cells infected with SEAP encoded baculovirus (seap-Ac.02; light
striped bars), and SfSWT4 and VESWT cells infected with a vankyrin enhanced baculovirus encoding SEAP (seap-AcVE.02; solid dark colored
bars) at an MOI of 1 is shown. Static cultures were grown in TNM-FH medium with FBS at a starting cell density of 5 3 105 cells mL21. Samples
were analyzed 3–5 days post-infection. The protein activity data presented are means and standard deviations for triplicate determinations for each
infection in a single experiment. The data presented here are representative of multiple (>3) experiments performed from which equivalent results
were obtained. Statistical significance as determined by the Student two-tailed t test for comparison of seap-Ac.02 infected SfSWT4 cells (white bar
with black stripes) vs. the other infected cells is represented by either one asterisk (*; P  0.05), two asterisks (P  0.01), or three asterisks
(P  0.002).

in the BEVS are unable to provide.32 In the present study,
we showed that a cell line engineered to overcome this limitation of the BEVS can be combined with vankyrinenhancement technology to further increase production levels
of humanized glycoproteins (Figures 4 and 5).
In summary, we document that vankyrin genes function to
significantly improve cell viability and thus protein yields in
baculovirus infected cells. Consequently, the VE-BEVS
offers a novel, significant, adaptable, and proven enhancement that substantially synergizes existing and improving
BEVS technologies.

Acknowledgments
The authors thank current and former members of the ParaTechs team for their guidance and input throughout this
project, especially Esther Fleming for cell line passaging and
Alisondra Maldanado for engineering the pVL-YFP vector.
They thank Algirdas Jesaitis for his evaluation of the VECL02 cell lines and their superior performance in purifying
the toxic components of flavocytochrome b558. Aspect of
this research have been orally presented by KS at several
scientific conferences: PEGS: the essential protein engineering summit (Boston MA, 2014), Peace Conference: protein
expression in animal cells (San Diego CA, 2015), International society for bioprocess technology (Washington DC,
2016), and Cell line development & engineering conference
(San Francisco CA, 2016). Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under
Award Numbers R42GM075628 and R44GM093411 to ParaTechs. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the
National Institute of Health. This technology was supported
in part by an award from the Kentucky Cabinet for Economic Development, Office of Entrepreneurship, under the
Grant Agreement KSTC-184–512-07–023 with the Kentucky
Science and Technology Corporation to ParaTechs. This article is subject to the NIH Public Access Policy.

Conflict of Interest Disclosure
The transfer vectors pAcVE.02 and pAcVE.03 and the
vankyrin enhanced VE-CL02 cell line are currently being
sold by ParaTechs Corporation. The VE-BEVS transfer vectors are under patent protection United States Patent
7,629,160, and the VE-CL02 cell line is protected under US
patent 7,842,493.

Literature Cited
1. Smith GE, Summers MD, Fraser MJ. Production of human beta
interferon in insect cells infected with a baculovirus expression
vector. Mol Cell Biol. 1983;3:2156–2165.
2. Pennock GD, Shoemaker C, Miller LK. Strong and regulated
expression of Escherichia coli b-galactosidase in insect cells
with a baculovirus vector. Mol Cell Biol. 1984;4:399–406.
3. Contreras-Gomez A, Sanchez-Miron A, Garcıa-Camacho F, MolinaGrima E, Chisti Y. Protein production using the baculovirus-insect
cell expression system. Biotechnol Prog. 2014;30:1–18.
4. van Oers MM, Pijlman GP, Vlak JM. Thirty years of
baculovirus-insect cell protein expression: from dark horse to
mainstream technology. J Gen Virol. 2015;96:6–23.
5. Berger I, Fitzgerald DJ, Richmond TJ. Baculovirus expression
system for heterologous multiprotein complexes. Nat Biotechnol.
2004;22:1583–1587.
6. Bieniossek C, Imasaki T, Takagi Y, Berger I. MultiBac: expanding the research toolbox for multiprotein complexes. Trends
Biochem Sci. 2012;37:49–57.
7. Fitzgerald DJ, Berger P, Schaffitzel C, Yamada K, Richmond
TJ, Berger I. Protein complex expression by using multigene
baculoviral vectors. Nat Methods. 2006;3:1021–1032.
8. Vijayachandran LS, Viola C, Garzoni F, Trowitzsch S,
Bieniossek C, Chaillet M, Schaffitzel C, Busso D, Romier C,
Poterszman A, Richmond TJ, Berger I. Robots, pipelines, polyproteins: enabling multiprotein expression in prokaryotic and
eukaryotic cells. J Struct Biol. 2011;175:198–208.
9. Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D,
Corazza Y, Lockman L, Giannini S, Deschamps M. Molecular and
structural characterization of the L1 virus-like particles that are used
as vaccine antigens in CervarixTM, the AS04-adjuvanted HPV-16
and 218 cervical cancer vaccine. Hum Vaccine. 2010;6:407–419.
10. Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and
immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines. 2015;3:97–108.

1506
1506
11. Lepenies B, Seeberger PH. The promise of glycomics, glycan
arrays and carbohydrate-based vaccines. Immunopharmacol
Immunotoxicol. 2010;32:196–207.
12. Blissard GW, Rohrmann GF. Baculovirus diversity and molecular biology. Annu Rev Entomol. 1990;35:127–155.
13. Thomas CJ, Brown HL, Hawes CR, Lee BY, Min M-K, King
LA, Possee RD. Localization of a baculovirus-induced chitinase
in the insect cell endoplasmic reticulum. J Virol. 1998;72:
10207–10212.
14. Hodgson JJ, Arif BM, Krell PJ. Interaction of Autographa californica multiple nucleopolyhedrovirus cathepsin protease progenitor (proV-CATH) with insect baculovirus chitinase as a
mechanism for proV-CATH cellular retention. J Virol. 2011;85:
3918–3929.
15. Kaba SA, Salcedo AM, Wafula PO, Vlak JM, van Oers MM.
Development of a chitinase and v-cathepsin negative bacmid for
improved integrity of secreted recombinant proteins. J Virol
Methods. 2004;122:113–118.
16. Park EY, Abe T, Kato T. Improved expression of fusion protein
using a cysteine- protease- and chitinase-deficient Bombyx mori
(silkworm) multiple nucleopolyhedrovirus bacmid in silkworm
larvae. Biotechnol Appl Biochem. 2008;49:135–140.
17. Ho Y, Lo HR, Lee TC, Wu CP, Chao YC. Enhancement of correct protein folding in vivo by a non-lytic baculovirus. Biochem
J. 2004;382:695–702.
18. Gomez-Sebastian S, Lopez-Vidal J, Escribano JM. Significant
productivity improvement of the baculovirus expression vector
system by engineering a novel expression cassette. PLoS One.
2014;9:e96562.
19. Lin G, Li G, Granados RR, Blissard GW. Stable cell lines
expressing baculovirus P35: resistance to apoptosis and nutrient
stress, and increased glycoprotein secretion. In Vitro Cell Dev
Biol Anim. 2001;37:293–302.
20. Griffiths CM, Barnett AL, Ayres MD, Windass J, King LA,
Possee RD. In vitro host range of Autographa californica nucleopolyhedrovirus recombinants lacking functional p35, iap1 or
iap2. J Gen Virol. 1999;80:1055–1066.
21. Ikeda M, Yamada H, Ito H, Kobayashi M. Baculovirus IAP1
induces caspase-dependent apoptosis in insect cells. J Gen Virol.
2011;92:2654–2663.
22. Kroemer JA, Webb BA. Divergences in protein activity and cellular localization within the Campoletis sonorensis Ichnovirus
Vankyrin family. J Virol. 2006;80:12219–12228.
23. Kroemer JA, Webb BA. Ikappabeta-related vankyrin genes in
the Campoletis sonorensis ichnovirus: temporal and tissuespecific patterns of expression in parasitized Heliothis virescens
lepidopteran hosts. J Virol. 2005;79:7617–7628.
24. Fath-Goodin A, Kroemer JA, Webb BA. The Campoletis sonorensis ichnovirus vankyrin protein P-vank-1 inhibits apoptosis in
insect Sf9 cells. Insect Mol Biol. 2009;18:497–506.
25. Bitra K, Suderman RJ, Strand MR. Polydnavirus Ank proteins
bind NF-jB homodimers and inhibit processing of Relish. PLoS
Pathog. 2012;8:e1002722.
26. Gueguen G, Kalamarz ME, Ramroop J, Uribe J, Govind S. Polydnaviral ankyrin proteins aid parasitic wasp survival by coordinate and selective inhibition of hematopoietic and immune NFkappa B signaling in insect hosts. PLoS Pathog. 2013;9:
e1003580.
27. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci.
2005;94:1626–1635.
28. Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an
effective strategy to optimize efficacy. BioDrugs Clin Immunotherap Biopharma Gene Ther. 2010;24:9–21.
29. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISSPROT database. Biochim Biophys Acta. 1999;1473:4–8.
30. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol.
2014;32:992–1000.
31. Geisler C, Jarvis DL. Insect cell glycosylation patterns in the
context of biopharmaceuticals. In: Walsh G, editor. Post-translational Modifications in the Context of Biopharmaceuticals, 1st
ed. Weinheim: Wiley-VCH; 2009:165–191.

Biotechnol.
Prog.,
2017,Vol.
Vol.33,
33,No.
No. 66
Biotechnol.
Prog.,
2017,
32. Geisler C, Mabashi-Asazuma H, Jarvis DL. An overview and
history of glyco-engineering in insect expression systems. Methods Mol Biol. 2015;1321:131–152.
33. Shi X, Jarvis DL. Protein N-glycosylation in the baculovirusinsect cell system. Curr Drug Targets. 2007;8:1116–1125.
34. Mena JA, Kamen AA. Insect cell technology is a versatile and
robust vaccine manufacturing platform. Expert Rev Vaccines.
2011;10:1063–1081.
35. Ikonomou L, Schneider Y-J, Agathos SN. Insect cell culture for
industrial production of recombinant proteins. Appl Microbiol
Biotechnol. 2003;62:1–20.
36. Vicente T, Rold~ao A, Peixoto C, Carrondo MJ, Alves PM.
Large-scale production and purification of VLP-based vaccines.
J Invertebr Pathol. 2011;107:S42–S48.
37. Palmberger D, Klausberger M, Berger I, Grabherr R. MultiBac
turns sweet. Bioengineered. 2013;4:78–83.
38. Palmberger D, Wilson IB, Berger I, Grabherr R, Rendic D.
SweetBac: a new approach for the production of mammalianised
glycoproteins in insect cells. PLoS One. 2012;7:e34226.
39. Mabashi-Asazuma H, Shi X, Geisler C, Kuo CW, Khoo KH,
Jarvis DL. Impact of a human CMP-sialic acid transporter on
recombinant glycoprotein sialylation in glycoengineered insect
cells. Glycobiology. 2013;23:199–210.
40. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P,
Grabherr R. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a
comparison of two insect cell lines as production platforms for
influenza vaccines. Mol Biotechnol. 2010;45:226–234.
41. Morais VA, Serpa J, Palma AS, Costa T, Maranga L, Costa J.
Expression and characterization of recombinant human a-3/4fucosyltransferase III from Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tn) cells using the baculovirus expression system.
Biochem J. 2001;353:719–725.
42. Taticek RA, Choi C, Phan SE, Palomares LA, Shuler ML. Comparison of growth and recombinant protein expression in two
different insect cell lines in attached and suspension culture.
Biotechnol Prog. 2001;17:676–684.
43. Shibuya N, Goldstein IJ, Broekaert WF, Nsimba-Lubaki M,
Peeters B, Peumans WJ. The elderberry (Sambucus nigra L.)
bark lectin recognizes the Neu5Ac(a2–6)Gal/GalNAc sequence.
J Biol Chem. 1987;262:1596–1601.
44. Tessier DC, Thomas DY, Khouri HE, Laliberte F, Vernet T.
Enhanced secretion from insect cells of a foreign protein fused
to the honeybee melittin signal peptide. Gene. 1991;98:177–183.
45. Jarvis DL. Recombinant protein expression in baculovirusinfected insect cells. Methods Enzymol. 2014;536:149–163.
46. Schlaeger EJ, Kitas EA, Dorn A. SEAP expression in transiently
transfected mammalian cells grown in serum-free suspension
culture. Cytotechnology. 2003;42:47–55.
47. Zhang F, Murhammer DW, Linhardt RJ. Enzyme kinetics and
glycan structural characterization of secreted alkaline phosphatase prepared using the baculovirus expression vector system.
Appl Biochem Biotechnol. 2002;101:197–210.
48. Felberbaum RS. The baculovirus expression vector system: a
commercial manufacturing platform for viral vaccines and gene
therapy vectors. Biotechnol J. 2015;10:702–714.
49. Ji C, Wang Y, Guo X, Hartson S, Jiang H. A pattern recognition
serine proteinase triggers the prophenoloxidase activation cascade in the tobacco hornworm, Manduca sexta. J Biol Chem.
2004;279:34101–34106.
50. Takahashi D, Garcia BL, Kanost MR. Initiating protease with
modular domains interacts with b-glucan recognition protein to
trigger innate immune response in insects. Proc Natl Acad Sci
USA. 2015;112:13856–13861.
51. Wang Y, Jiang H. Interaction of beta-1,3-glucan with its recognition protein activates hemolymph proteinase 14, an initiation
enzyme of the prophenoloxidase activation system in Manduca
sexta. J Biol Chem. 2006;281:9271–9278.
52. Cieplik M, Klenk HD, Garten W. Identification and characterization of Spodoptera frugiperda furin: a thermostable subtilisinlike endopeptidase. Biol Chem. 1998;379:1433–1440.
53. Nguyen Q, Nielsen LK, Reid S. Genome scale transcriptomics of baculovirus-insect interactions. Viruses. 2013;5:2721–
2747.

Biotechnol. Prog.,
2017,
Vol. Vol.
33, No.
Biotechnol.
Prog.,
2017,
33,6 No. 6
54. Du X, Thiem SM. Responses of insect cells to baculovirus
infection: protein synthesis shutdown and apoptosis. J Virol.
1997;71:7866–7872.
55. Mazzacano CA, Du X, Thiem SM. Global protein synthesis
shutdown in Autographa californica nucleopolyhedrovirusinfected Ld652Y cells is rescued by tRNA from uninfected
cells. Virology. 1999;260:222–231.
56. Chen YR, Zhong S, Fei Z, Hashimoto Y, Xiang JZ, Zhang S,
Blissard GW. The transcriptome of the baculovirus Autographa
californica multiple nucleopolyhedrovirus in Trichoplusia ni
cells. J Virol. 2013;87:6391–6405.
57. Sisk WP, Bradley JD, Leipold RJ, Stoltzfus AM, Ponce de Leon
M, Hilf M, Peng C, Cohen GH, Eisenberg RJ. High-level
expression and purification of secreted forms of herpes simplex
virus type 1 glycoprotein gD synthesized by baculovirusinfected insect cells. J Virol. 1994;68:766–775.
58. Wicker-Planquart C, Canaan S, Rivière M, Dupuis L, Verger R.
Expression in insect cells and purification of a catalytically active
recombinant human gastric lipase. Protein Eng. 1996;9:1225–1232.
59. Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland
T, Watson E, Stebbing N. Erythropoietin: gene cloning, protein
structure, and biological properties. Cold Spring Harb Symp
Quant Biol. 1986;51(Part1):693–702.
60. Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood. 1989;73:84–89.
61. Higuchi M, Oh-eda M, Kuboniwa H, Tomonoh K, Shimonaka Y,
Ochi N. Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem. 1992;267:7703–7709.

1507
1507
62. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer.
2001;84:3–10.
63. Yang Y, Millan JL, Mecsas J, Guillemin K. Intestinal alkaline
phosphatase deficiency leads to lipopolysaccharide desensitization and faster weight gain. Infect Immun. 2015;83:247–258.
64. Kats S, Brands R, Seinen W, de Jager W, Bekker MW, Hamad
MA, Tan ME, Sch€onberger JP. Anti-inflammatory effects of
alkaline phosphatase in coronary artery bypass surgery with cardiopulmonary bypass. Recent Pat Inflamm Allergy Drug Discov.
2009;3:214–220.
65. Jarvis DL. Effects of baculovirus infection on IE1-mediated foreign gene expression in stably transformed insect cells. J Virol.
1993;67:2583–2591.
66. Jarvis DL, Oker-Blom C, Summers MD. Role of glycosylation
in the transport of recombinant glycoproteins through the secretory pathway of lepidopteran insect cells. J Cell Biochem. 1990;
42:181–191.
67. Fath-Goodin A, Kroemer J, Martin S, Reeves K, Webb BA. Polydnavirus genes that enhance the baculovirus expression vector
system. Adv Virus Res. 2006;68:75–90.
68. Toth AM, Kuo CW, Khoo KH, Jarvis DL. A new insect cell
glycoengineering approach provides baculovirus-inducible glycogene expression and increases human-type glycosylation efficiency. J Biotechnol. 2014;20:19–29.
Manuscript received Jan. 10, 2017, and revision received Mar. 21,
2017.

